Core Viewpoint - Marvell is conducting an accelerated share repurchase, which the CEO interprets as a demonstration of confidence in the business and the intrinsic value of the company's stock [1] Group 1 - The accelerated share repurchase indicates a strong belief in the company's future performance and stock valuation [1]

Core Insights - Darden Restaurants, Inc. reported strong financial results for the first quarter of fiscal 2026, with total sales increasing by 10.4% to $3.0 billion, driven by a same-restaurant sales increase of 4.7% and contributions from acquisitions [2][6][7]. Financial Performance - Consolidated sales for Q1 2026 were $3,044.7 million, compared to $2,757.0 million in Q1 2025, reflecting a growth of 10.4% [4]. - Same-restaurant sales growth was reported at 4.7%, with Olive Garden and LongHorn Steakhouse showing increases of 5.9% and 5.5%, respectively [2][4]. - Adjusted diluted net earnings per share from continuing operations increased by 12.6% to $1.97, up from $1.75 in the prior year [7][19]. Segment Performance - Olive Garden generated sales of $1,301.1 million in Q1 2026, with a segment profit of $267.6 million, compared to $1,209.1 million and $250.1 million in Q1 2025 [4]. - LongHorn Steakhouse reported sales of $776.4 million and a segment profit of $134.9 million, up from $713.5 million and $128.4 million, respectively [4]. - The Fine Dining segment experienced a slight decline in profit, with a segment profit of $38.7 million compared to $38.9 million in the previous year [4]. Shareholder Returns - The Board of Directors declared a quarterly cash dividend of $1.50 per share, payable on November 3, 2025 [5]. - During the quarter, the company repurchased approximately 0.9 million shares for a total of $183 million, with $865 million remaining under the current $1 billion repurchase authorization [8][7]. Future Outlook - The company updated its full-year financial outlook for fiscal 2026, projecting total sales growth of 7.5% to 8.5%, including approximately 2% growth related to the addition of a 53rd week [14]. - Same-restaurant sales growth is expected to be between 2.5% to 3.5%, with plans to open approximately 65 new restaurants [14].

Core Insights - First American Financial Corporation (FAF) announced a 2% increase in its quarterly cash dividend to 55 cents per share, reflecting its strong financial position and commitment to shareholders [1][2][9] - The new dividend yield is 3.2%, significantly higher than the industry average of 0.2%, making FAF an attractive option for yield-seeking investors [3][9] - FAF has a solid track record of dividend increases, with a nine-year compound annual growth rate (CAGR) of 5.5% [3][9] Financial Strength and Capital Management - FAF is committed to returning excess cash to shareholders through both dividend increases and share repurchases, with a new repurchase plan authorizing up to $300 million [4][5] - As of June 30, 2025, FAF had $114.2 million in cash and cash equivalents, along with $900 million available on its revolving credit facility, indicating strong liquidity [6][9] - The return on equity for FAF was 10.4%, outperforming the industry average of 7.6%, which supports its ability to sustain dividend payments [7] Market Performance - FAF shares have gained 9% year-to-date, outperforming the industry growth of 7.5%, indicating positive market momentum [8] - The company's strategy of enhancing growth and capital position is expected to help maintain this momentum [8]

Core Viewpoint - Sphere Entertainment Co. has repurchased a total of 425,219 shares of its Class A common stock at an average price of $52.91 per share, amounting to approximately $22.5 million from September 3, 2025, to September 11, 2025 [1] Summary by Relevant Sections - **Share Repurchase Details** - The company repurchased 425,219 shares of SPHR Class A common stock at an average price of $52.91 per share [1] - The total aggregate purchase price for this repurchase was approximately $22.5 million [1] - The repurchases were funded using cash on hand [1] - To date, the company has repurchased a total of 1,054,247 shares of SPHR Class A common stock [1]

Core Points - Restaurant Brands International Inc. (RBI) intends to renew its normal course issuer bid (NCIB) for common shares, allowing for the repurchase of up to U.S.$1,000 million of shares through September 30, 2027 [1][2] - The new repurchase authorization replaces the previous two-year authorization set to expire on September 30, 2025, and reflects RBI's commitment to capital allocation flexibility while prioritizing debt reduction [1][4] - Under the NCIB, RBI may purchase up to 32,326,078 common shares, representing 10% of its public float as of September 2, 2025, during the period from September 16, 2025, to September 15, 2026 [2][3] Company Overview - RBI is one of the largest quick service restaurant companies globally, with nearly $45 billion in annual system-wide sales and over 32,000 restaurants in more than 120 countries [5] - The company owns four prominent brands: TIM HORTONS®, BURGER KING®, POPEYES®, and FIREHOUSE SUBS®, which have been serving customers for decades [5] - RBI is focused on improving sustainable outcomes related to food, the planet, and communities through its Restaurant Brands for Good framework [5]

Core Viewpoint - Bill Holdings' CEO defends the company's performance amid pressure from activist hedge funds seeking changes in the board [1][3] Company Performance - The CEO highlighted that the company has doubled its revenue and non-GAAP profits over the past three years, with a GAAP net profit of $24 million for the 2025 fiscal year after three years of losses totaling $579 million [4] - Bill's shares have declined 37% this year and are approximately 85% below their peak of $342 in November 2021 [6] Market Position and Strategy - Bill targets small and midsized businesses (SMBs), with a current market penetration of only 4%, indicating significant growth opportunities [5] - The company is focused on better monetizing its existing client base and expanding its payment products [5][6] Competitive Landscape - Bill faces increased competition from rivals such as Intuit and Tipalti, which has pressured its revenue growth [7] - Financial uncertainty among SMB customers due to external factors, including tariffs and economic outlook, has also impacted performance [7] Shareholder Actions - The board has authorized a new $300 million share repurchase program, in addition to $100 million in shares repurchased so far in 2025 [6] - Activist hedge funds Starboard Value and Elliott Investment Management have taken significant stakes in the company, with Starboard seeking to add directors to the board [3][8]

Core Viewpoint - Newmont has applied for voluntary delisting from the Toronto Stock Exchange due to low trading volumes, aiming to enhance administrative efficiency and reduce costs [1] Group 1: Delisting and Cost Management - The delisting is expected to be effective around September 24, which may lead to improved administrative efficiency and cost reduction [1] - Newmont has set a target to reduce costs by $300 per ounce, potentially resulting in thousands of layoffs [1] Group 2: Asset Divestment and Financial Strategy - Following its $17.14 billion acquisition of Newcrest, Newmont announced plans to divest non-core assets, reduce workforce, and cut debt [2] - The company has divested several Canadian assets, including the Eleonore mine for approximately $795 million, the Musselwhite Gold Mine for $850 million, and its stake in Porcupine Operations for $425 million [2] Group 3: Current Operations and Share Repurchase - Newmont continues to operate the Brucejack and Red Chris mines in Canada [3] - The company announced a $3 billion share repurchase program in July during its second-quarter results [3] - Newmont will maintain its primary listing on the New York Stock Exchange and support listings on the Australian Securities Exchange and the Papua New Guinea Stock Exchange [3] Group 4: Delisting Approval - Newmont does not intend to seek security holder approval for the delisting, as shares are currently trading on alternative markets [4]

Financial Data and Key Metrics Changes - Q2 net sales grew by nearly 9% year over year to $3.1 billion, exceeding the high end of guidance [6][19] - Gross margin reached 30.4%, expanding by nearly 80 and 90 basis points sequentially and year-over-year, respectively [8][19] - Adjusted EBITDA was $183.3 million, representing a 5.9% margin and a year-over-year increase of over 80 basis points [9][21] - Free cash flow generated was nearly $106 million in the quarter [9][21] - Adjusted net income increased by 34.8% year over year to $141.1 million, with adjusted diluted earnings per share of $0.33 [21][25] Business Line Data and Key Metrics Changes - Autoship customer sales reached $2.58 billion, representing 83% of Q2 net sales and growing nearly 15% year over year [6][7] - Hardgoods business grew over 15% in Q2, driven by structural volume growth [7] - Chewy Plus program showed strong growth, with approximately 3% of total monthly sales attributed to members [11][12] Market Data and Key Metrics Changes - Active customers increased to 20.9 million, reflecting 4.5% year-over-year growth [8] - NESPAC (Net Effective Sales Per Active Customer) reached $591, representing 4.6% year-over-year growth [8] Company Strategy and Development Direction - Chewy is focused on expanding its Chewy Plus membership and private brands, with a new product line "Get Real" launched for fresh dog food [12][15] - The company aims to mitigate tariff-related costs and invest in growth initiatives while maintaining a strong customer experience [17] - Chewy plans to open 8 to 10 new veterinary practices in fiscal year 2025, enhancing its Chewy Vet Care network [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Chewy's ability to gain market share despite a challenging retail environment [17] - The company anticipates continued growth in the second half of 2025, with net sales expected to be between $3.07 and $3.1 billion [23] - Management expects to maintain a full-year adjusted EBITDA margin outlook of 5.4% to 5.7% [24] Other Important Information - The company repurchased approximately 3 million shares for a total of approximately $125 million in Q2 [21][22] - Chewy ended the quarter with approximately $592 million in cash and cash equivalents, remaining debt-free [22][23] Q&A Session Summary Question: Investments required in the back half and increasing awareness of new offerings - Management indicated that they are focusing on existing members for Chewy Plus and have not spent additional marketing dollars externally [27][28] Question: SG&A deleverage and its components - Management expects SG&A leverage in 2025, with temporary costs attributed to the ramp-up of the Houston fulfillment center and higher inventory processing costs [36][42] Question: Q2 gross margin improvement and pricing investments - Management noted that gross margin drivers include product mix, increasing Autoship penetration, and a rational promotional environment [45][46] Question: Potential of the fresh and frozen segment - Management estimates the total addressable market for fresh and frozen pet food to be between $8 billion and $12 billion, with strong initial customer reception for the "Get Real" product line [55][56] Question: Advertising environment and macro expectations - Management reported stable pet household formation trends and competitive intensity in advertising, with expectations for continued customer growth [60][66] Question: Competitive advantages and share gains - Management emphasized Chewy's unique value proposition, combining e-commerce efficiency with personalized service, and highlighted growth opportunities in health and wellness segments [70][76] Question: Quality of customer cohorts and Autoship growth - Management noted improvements in customer retention and engagement through programs like Autoship and Chewy Plus, leading to higher NESPAC [79][82]

Summary of Prothena's Conference Call Company Overview - **Company**: Prothena - **Industry**: Biotechnology, specifically focused on neurodegenerative diseases and amyloidosis Key Points and Arguments 1. **Pipeline Updates**: Prothena has made significant progress in its pipeline, with Roche advancing prasinezumab for Parkinson's disease into a phase three study and Novo moving Kuramitug for ATTR cardiomyopathy into a phase three study as well [4][5] 2. **Restructuring**: The company underwent a restructuring to align its resources with ongoing partnership obligations and to focus on shareholder-friendly activities [13][14] 3. **Financial Milestones**: Prothena anticipates up to $105 million in clinical milestone payments in 2026, contingent on the progress of its partnered programs with Novo and Bristol Myers Squibb [8][16] 4. **Shareholder Returns**: Plans for a share repurchase program are in place, supported by the establishment of distributable reserves through an extraordinary general meeting [11][20] 5. **PRXO12 Data**: The recent data for PRXO12 indicated higher than expected ARIA events, prompting consideration of a transferrin-based approach to mitigate these issues while retaining the drug's efficacy [21][24] 6. **Partnerships**: Prothena has four partnership programs, with two in phase three and one in phase two, which are crucial for the company's future value creation [12][19] 7. **Roche Partnership**: The deal with Roche is valued at $755 million, with $135 million received to date. Roche sees a peak sales opportunity for prasinezumab exceeding $4 billion [32][33] 8. **Novo Partnership**: The partnership with Novo for Kuramitug is valued at $1.23 billion, with $100 million received so far. The next milestone payment is expected to be around $50 million [60][63] 9. **Clinical Development**: Prothena is focused on the clinical development of its partnered assets, with expectations for data releases from ongoing studies [39][70] Additional Important Content 1. **Market Potential**: The market for treatments targeting neurodegenerative diseases and amyloidosis is significant, with increasing demand for effective therapies [43][58] 2. **Competitive Landscape**: The competitive environment is intensifying, with multiple companies developing similar therapies, which could impact Prothena's market positioning [21][22] 3. **Regulatory Considerations**: The timeline for potential partnerships and clinical trials is uncertain, with ongoing discussions expected to take time [29][30] 4. **Scientific Insights**: Prothena's approach to targeting alpha-synuclein in Parkinson's disease is based on empirical data, focusing on the carboxy terminus of the protein for better efficacy [44][46] This summary encapsulates the critical insights from Prothena's conference call, highlighting the company's strategic direction, financial outlook, and ongoing clinical developments.

Core Viewpoint - Thomson Reuters has announced a $1.0 billion share repurchase program and entered into an automatic share purchase plan to facilitate share purchases during blackout periods [1][2]. Group 1: Share Repurchase Program - The company plans to repurchase up to 10 million common shares between August 19, 2025, and August 18, 2026, as part of its normal course issuer bid (NCIB) [1]. - The automatic share purchase plan (ASPP) allows the company to buy shares during periods when it would typically be restricted from doing so due to regulatory reasons [2]. - All purchases made under the ASPP will count towards the total shares repurchased under the NCIB [2]. Group 2: Conditions and Management Discretion - Purchases under the ASPP will be executed by the company's broker based on parameters set by Thomson Reuters, ensuring no material non-public information is involved [2]. - Outside of predetermined blackout periods, share purchases will be at management's discretion, adhering to TSX rules and applicable securities laws [2]. - Future repurchase decisions will depend on market conditions, share price, and other investment opportunities [3].